Market Movers: Bioventus (BVS) Drops 5.04% to Close at $8.67 June 21

Equities Staff  |

Bioventus Inc - Class A (NASDAQ:BVS) stock was among today's market movers, ending trading lower 5.04% to $8.67 on June 21.

284,691 shares traded hands compared to the 30-day daily average of 225,192 shares.

The company's stock dropped 36.99% so far in 2022.

Bioventus shares have traded in a range between $7.31 and $19.94 over the past twelve months.

For technical charts, analysis, and more on Bioventus visit the company profile.

About Bioventus Inc - Class A

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.

To get more information on Bioventus Inc - Class A and to follow the company's latest updates, you can visit the company's profile page here: Bioventus Inc - Class A's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content